Fair 50°
Tag:

Clinical Trials

News
COVID-19: Pfizer Asks FDA For Emergency Use Authorization Of Vaccine For Children Under 5 COVID-19: Pfizer Asks FDA For Emergency Use Authorization Of Vaccine For Children Under 5
Covid-19: Pfizer Asks FDA For Emergency Use Authorization Of Vaccine For Children Under 5 New York-based Pfizer and its European partner BioNTech has requested that the Food and Drug Administration (FDA) expand the use of its COVID-19 vaccine to include children between the ages of 6 months and 5 years old, officials announced. On Tuesday, Feb. 1, citing a host of clinical trials, the pharmaceutical company announced it is seeking emergency use authorization (EUA) to admit the vaccine to a wider range of children. Currently, the vaccine is only approved for children 5 years old and older. Pfizer said that it plans to complete its EUA submission “in the coming days,” and has alre…

SHARE

by Zak Failla
News
COVID-19: Booster Shot Significantly Raises Antibody Levels Against Omicron, Moderna Says COVID-19: Booster Shot Significantly Raises Antibody Levels Against Omicron, Moderna Says
Covid-19: Booster Shot Significantly Raises Antibody Levels Against Omicron, Moderna Says A Moderna COVID-19 vaccine booster shot significantly raises the level of antibodies against the new Omicron variant, the company announced on Monday morning, Dec. 20. The currently authorized 50-microgram booster neutralized antibody levels against Omicron approximately 37-fold compared to pre-boost levels and a 100-micrograms dose increased neutralizing antibody levels approximately 83-fold compared to pre-boost levels, the Cambridge, Massachusetts-based company said in a statement. The results are based on laboratory testing. “The dramatic increase in COVID-19 cases from the O…

SHARE

by Joe Lombardi
News
COVID-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus COVID-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus
Covid-19: Drugmaker To Seek Emergency Approval For Pill To Treat Virus A new pharmaceutical company is throwing its hat in the ring as the country continues its fight against COVID-19. Merck and Ridgeback Biotherapeutics announced on Friday, Oct. 1 that it is planning to apply for federal emergency approval of a pill that can reportedly help prevent hospitalizations and deaths in COVID-19 patients. According to the company, trials have found that the pill - dubbed molnupiravir - could potentially reduce the risk of hospitalization or death in patients with mild to moderate COVID-19 by approximately 50 percent. The results of the late-stage trial have bee…

SHARE

by Zak Failla